{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:06:30Z","timestamp":1793142390919,"version":"4.5.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Peyronie\u2019s disease (PD) is a progressive fibrotic disorder of the penis that is adverse to men\u2019s health. Currently, effective and reliable non-surgical options for PD are limited. Since the Food and Drug Administration (FDA) approved it in 2013, intralesional injection of collagenase <jats:italic>Clostridium histolyticum<\/jats:italic> (CCH) became the only licensed treatment for PD. This meta-analysis aims to evaluate the clinical efficacy and safety of CCH in treating PD, predominantly based on post-FDA studies.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The primary outcome was clinical efficacy evaluated by the percentages of improvement in penile curvature (PC) and Peyronie\u2019s disease symptom bother score (PD bother score). The secondary outcome was the safety assessed by treatment-related adverse events (TRAEs). Heterogeneity was assessed by Cochran\u2019s Q and <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup> tests. Sensitivity and subgroup analyses were performed to explore the source of heterogeneity. Funnel plots and Egger\u2019s test were used to evaluate the publication bias.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 11 studies with 1,480 intentions to treat (ITT) population were included. The pooled effect of the improvement of PC was 35% (95% CI: 0.33\u20130.38), and the pooled improvement of the PD bother score was 41% (95% CI: 0.37\u20130.45). No heterogeneity was found at the pooled improvement of PC (<jats:italic>p<\/jats:italic> = 0.845, <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup> = 0.00%). Meanwhile, some heterogeneity existed in the pooled improvement of the PD bother score (<jats:italic>p<\/jats:italic> = 0.069, <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup> = 43.4%). The pooled effect of TRAEs was 93% (95% CI 0.88\u20130.97) with significant heterogeneity (<jats:italic>p<\/jats:italic> &amp;lt; 0.000, <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup> = 92.3%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The intralesional injection of CCH could significantly improve the penile deformity of PD patients. Meanwhile, CCH appears to ameliorate the PD bother score to some extent and has acceptable clinical safety. Future studies are required to clarify the long-term outcomes of CCH injection in the treatment of PD.<\/jats:p>","DOI":"10.3389\/fphar.2022.973394","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T05:57:02Z","timestamp":1664949422000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The efficacy and safety of intralesional injection of collagenase Clostridium histolyticum for Peyronie\u2019s disease: A meta-analysis of published prospective studies"],"prefix":"10.3389","volume":"13","author":[{"given":"Fuxun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s40265-016-0649-1","article-title":"Collagenase Clostridium histolyticum for the treatment of peyronie's disease: A 'real world' clinical perspective","volume":"76","author":"Anaissie","year":"2016","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11934-018-0800-5","article-title":"Contemporary review of Peyronie's disease treatment","volume":"19","author":"Capoccia","year":"2018","journal-title":"Curr. Urol. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.sxmr.2017.12.006","article-title":"Objective assessments of Peyronie's disease","volume":"6","author":"Chen","year":"2018","journal-title":"Sex. Med. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/bju.15057","article-title":"A clinical pathway for the management of peyronie's disease: Integrating clinical guidelines from the international society of sexual medicine, American urological association and European urological association","volume":"126","author":"Chung","year":"2020","journal-title":"BJU Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","article-title":"Evidence-based management guidelines on peyronie's disease","volume":"13","author":"Chung","year":"2016","journal-title":"J. Sex. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40265-015-0441-7","article-title":"Collagenase clostridium histolyticum: A review in peyronie's disease","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.sxmr.2017.03.005","article-title":"Collagenase clostridium histolyticum in the treatment of urologic disease: Current and future impact","volume":"6","author":"Gabrielson","year":"2018","journal-title":"Sex. Med. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00345-019-02817-4","article-title":"Managing complications of collagenase Clostridium histolyticum (CCH) injection","volume":"38","author":"Greear","year":"2020","journal-title":"World J. Urol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.sxmr.2015.10.002","article-title":"The genetic basis of Peyronie disease: A review","volume":"4","author":"Herati","year":"2016","journal-title":"Sex. Med. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40261-019-00867-5","article-title":"Collagenase clostridium histolyticum: A review in peyronie's disease","volume":"40","author":"Hoy","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13051","DOI":"10.1111\/and.13051","article-title":"Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-\u03b2\/SMAD signalling pathway","volume":"50","author":"Li","year":"2018","journal-title":"Andrologia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/BTT.S65619","article-title":"Role of collagenase clostridium histolyticum in Peyronie's disease","volume":"29","author":"Peak","year":"2015","journal-title":"Biologics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.jsxm.2019.03.404","article-title":"Current strategies in the management of Peyronie's disease (PD)-results of a survey of 401 sexual medicine experts across Europe","volume":"16","author":"Porst","year":"2019","journal-title":"J. Sex. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1756287218823671","DOI":"10.1177\/1756287218823671","article-title":"Non-invasive treatment in the management of Peyronie's disease","volume":"11","author":"Randhawa","year":"2019","journal-title":"Ther. Adv. Urol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jsxm.2018.12.011","article-title":"Comparative effectiveness of intralesional therapy for peyronie's disease in controlled clinical studies: A systematic review and network meta-analysis","volume":"16","author":"Russo","year":"2019","journal-title":"J. Sex. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2018.07.005","article-title":"Clinical efficacy of injection and mechanical therapy for peyronie's disease: A systematic review of the literature","volume":"74","author":"Russo","year":"2018","journal-title":"Eur. Urol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41585-018-0117-7","article-title":"Nonsurgical management of Peyronie's disease","volume":"16","author":"Tsambarlis","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.jsxm.2019.06.010","article-title":"Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie's disease in an era of effective clinical treatment","volume":"16","author":"Wymer","year":"2019","journal-title":"J. Sex. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"643641","DOI":"10.3389\/fphar.2021.643641","article-title":"Molecular mechanisms and current pharmacotherapy of peyronie's disease: A review","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/iju.14230","article-title":"Peyronie's disease: Contemporary evaluation and management","volume":"27","author":"Ziegelmann","year":"2020","journal-title":"Int. J. Urol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.973394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T05:57:05Z","timestamp":1664949425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.973394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":21,"alternative-id":["10.3389\/fphar.2022.973394"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.973394","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"article-number":"973394"}}